Abstract
Background
Helicobacter pylori eradication therapies are commonly employed to ameliorate gastric mucosal inflammation, facilitate ulcer healing, and mitigate the risk of gastric cancer. However, several challenges are associated with H. pylori eradication. Firstly, diverse treatment protocols are currently utilized globally, with variations based on geographical regions and countries. Secondly, the emergence of antimicrobial resistance in H. pylori is exacerbated by indiscriminate antibiotic usage. Lastly, there is a potential for gut microbiota dysbiosis resulting from H. pylori treatment.
Method
A retrospective study was conducted on patients who had diagnosed with H. Pylori and were treated in Suwayda Hospital.
Results
In our study, a cohort of 96 patients was examined, with an average age of 47.11 years. The majority of the sample consisted of female patients, totaling 59 individuals. The predominant symptom observed in 89 patients was epigastric pain, while the primary diagnostic approach for H. pylori patients involved upper gastrointestinal endoscopy with biopsies, as utilized in 94 cases. The majority of patients (85 individuals) underwent triple therapy for H. pylori eradication, whereas a smaller subset (9 patients, constituting 9%) received quadruple therapy.
Conclusion
Enhancing our comprehension of immune system dynamics across various age groups—where childhood tends to sustain infection persistence and adulthood is associated with gastric damage—can inform the formulation of strategies aimed at reducing H. pylori prevalence, including vaccine development, and mitigating adverse clinical consequences related to infection.